|1.||Berg, Thomas: 3 articles (01/2014 - 10/2006)|
|2.||Mauss, Stefan: 3 articles (12/2011 - 10/2006)|
|3.||Amini-Bavil-Olyaee, Samad: 3 articles (10/2009 - 11/2006)|
|4.||Sheldon, Julie: 3 articles (04/2009 - 10/2006)|
|5.||Yuan, Zhenghong: 2 articles (02/2015 - 08/2010)|
|6.||Chen, Jieliang: 2 articles (02/2015 - 08/2010)|
|7.||Gurel, Selim: 2 articles (04/2014 - 01/2011)|
|8.||Gane, Edward: 2 articles (04/2014 - 01/2011)|
|9.||van Bömmel, Florian: 2 articles (01/2014 - 01/2012)|
|10.||Hu, Jianming: 2 articles (09/2013 - 09/2013)|
|1.||Chronic Hepatitis B
01/01/2015 - "In the present study, a total of 168 serum samples from treatment-naive chronic hepatitis B (CHB) patients were collected, and the RT region of HBV polymerase was sequenced. "
10/01/2009 - "Our study reveals that rtQ215 substitutions in the HBV polymerase frequently occur in chronic hepatitis B, even without exogenous selection pressures. "
01/01/2015 - "In order to investigate the mutation of HBV polymerase gene reverse transcription conserved region (P region) in chronic hepatitis B (CHB) patients, 212 CHB patients who took antiretroviral treatment with nucleotide analogues were chosen. "
09/01/2013 - "Resistance to antiviral treatment for chronic hepatitis B virus (HBV) has been associated with mutations in the HBV polymerase region. "
12/01/2011 - "Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B."
08/01/2010 - "Further studies showed that HBV polymerase inhibited phosphorylation, dimerization and nuclear translocation of IRF3, in response to Sendai virus infection. "
11/28/2013 - "Based on these data it is suggested that during HBV infection the final import of the genome complex into the nucleus is mediated by a novel bipartite NLS localized in the TP domain of HBV polymerase."
08/01/2010 - "In addition, HBV polymerase blocked cellular IFN-beta expression and consequent antiviral immunity revealed by an infection protection assay. "
05/01/2009 - "Prior to the HBV mutant challenge of vaccinated chimpanzees, we established virologic, serologic, and pathologic characteristics of infections resulting from intravenous inoculation of the HBV polymerase gene mutant and the sG145R vaccine-escape surface gene mutant. "
03/01/2009 - "Although clinically insufficient, this effect indicates that HBV polymerase resistance mutations may be antagonistic, which is relevant if chronic HBV infection is to be treated by a combination of polymerase inhibitors."
10/01/2015 - "Successful antiviral treatment of decompensated hepatitis B with HBV polymerase inhibitors is associated with improvement of liver function. "
08/01/2009 - "Mutations in the HBV polymerase that confer resistance to nucleoside and nucleotide analog treatments are a major barrier to the success of therapy for hepatitis B. "
02/01/2010 - "Further prospective studies for hepatitis B viral load using HBV-polymerase chain reaction in patients who are HbcAb positive are needed to identify whether the abnormal LFT comes from the reactivation of occult HBV infection."
01/01/2012 - "In 10 HBV-monoinfected patients (9 male, mean age 47 ±11 [range 27-67] years, 6 hepatitis B e antigen-positive) with virological breakthrough during ADV treatment associated with the mutations rtN236T and/or rtA181T/V, HBV polymerase gene variants were studied during up to 24 months of consecutive monotherapy with TDF by population sequencing, line probe assay and clonal analysis. "
09/01/2003 - "[Detection of the mutation in HBV polymerase gene by RFLP PCR method in hepatitis B patients treated with lamivudine]."
01/01/2009 - "Lamivudine reduces HBv viremia, but favors the emergence of HBv polymerase gene mutants and should be individually discussed. "
01/01/2000 - "Several mutations (V521L, P525L, L528M, T532S, and V555I) in the gene for hepatitis B virus (HBV) polymerase have been identified in HBV isolated from patients that displayed break-through viremia during famciclovir treatment. "
09/12/2008 - "We investigated the addition of entecavir, a potent inhibitor of HBV polymerase, to lamivudine-containing highly active antiretroviral therapy (HAART) in patients who experienced rebound in HBV viremia while maintaining suppression of plasma HIV RNA less than 400 copies/ml. Sixty-eight patients were randomized to entecavir 1 mg (n = 51) or placebo (n = 17) once daily for 24 weeks; 65 patients continued the study with entecavir for an additional 24 weeks. "
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
|4.||Aspartic Acid (Aspartate)
|5.||tenofovir disoproxil (Viread)
|6.||adefovir dipivoxil (Hepsera)
|7.||hepatitis B hyperimmune globulin
|8.||DNA (Deoxyribonucleic Acid)
|9.||Hepatitis B e Antigens
|1.||Transplantation (Transplant Recipients)
|3.||Highly Active Antiretroviral Therapy (HAART)
|5.||Renal Dialysis (Hemodialysis)